Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species

Li, Chun; Yang, Yanling; Ren, Linzhu

doi:10.1016/j.meegid.2020.104285

Cited by 149 publications

(155 citation statements)

References 15 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Animal coronaviruses rarely infect humans and then spread between people with the exceptions of the Middle East Respiratory Syndrome (MERS-CoV), the Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV), and now the SARS-CoV-2, the cause of the ongoing COVID-19 pandemic. SARS-CoV-2 virus is a novel coronavirus characterized by a linear, positive-sense single-stranded RNA genome of about 30kb with a 86% similarity with the SARS-CoV genome [1][2][3]. Moreover, it has a high level of homology with SARS-like coronavirus isolated in bats and pangolins suggesting that it first originated in bats, being pangolins the intermediate hosts for humans [3].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test

Comar

Brumat

Concas

et al. 2020

Preprint

View full text Add to dashboard Cite

The fast spread of the novel coronavirus (SARS-CoV-2) has become a global threat hitting the worldwide fragile health care system. In Italy, there is a continued COVID-19 growth of cases and deaths that requires control measures for the correct management of the epidemiological emergency. To contribute to increasing the overall knowledge of COVID-19, systematic tests in the general population are required.Here, we describe the first Italian survey performed in 727 employees belonging to a Mother-Child Research hospital tested for both viral (nasopharyngeal and oropharyngeal swabs) and antibody presence. Individuals were divided into three risk categories (high, medium and low) according to their job activity. Only one subject was positive at the swab test while 17.2% of the cohort was positive for the presence of antibodies. Results highlighted that the presence of Positive antibodies is significantly associated with high and medium risk exposure occupation (p-value=0.026) as well as cold and conjunctivitis symptoms (p-value=0.016 and 0.042 respectively). Moreover, among healthcare professionals, the category of medical doctors showed a significant association with the presence of antibodies against SARS-CoV-2 (p-value=0.0127). Finally, we detected a rapid decrease in antibody intensity between two assessments performed within a very short period (p-value=0.009). Overall, the present study increases our knowledge of the epidemiological data of COVID-19 infection in Italy, suggesting a high prevalence of immune individuals (i.e. at least among at-risk categories) and the efficacy of the combined diagnostic protocol to monitor the possible outbreak.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test

Comar

Brumat

Concas

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The available data suggest that the combinant receptor binding domain (RBD) portion of the SARS-CoV-2 S protein has evolved to effectively target ACE2. The SARS-CoV-2 S protein is so effective at binding human cells that the scientific community has concluded it is the result of natural selection [14][15][16]. The same is true of its backbone and overall molecular structure [17].…”

Section: The Virus Responsible For Covid-19mentioning

confidence: 99%

Toward understanding the 2019 Coronavirus and its impact on the heart

Becker¹

2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

“…The novel SARS-CoV-2 shares 80% of identity with SARS-CoV (the causing agent of the 2002-2003 SARS outbreak in Asia) and nearly 96% similar to the bat coronavirus isolate RaTG13, suggesting these animals are the likely natural reservoir of the virus [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

CoV2ID: Detection and Therapeutics Oligo Database for SARS-CoV-2

Carneiro¹,

Pereira

2020

Preprint

View full text Add to dashboard Cite

The ability to detect the SARS-CoV-2 in a widespread epidemic is crucial for screening of carriers and for the success of quarantine efforts. Methods based on real-time reverse transcription polymerase chain reaction (RT-qPCR) and sequencing are being used for virus detection and characterization. However, RNA viruses are known for their high genetic diversity which poses a challenge for the design of efficient nucleic acid-based assays. The first SARS-CoV-2 genomic sequences already showed novel mutations, which may affect the efficiency of available screening tests leading to false-negative diagnosis or inefficient therapeutics.Here we describe the CoV2ID(http://covid.portugene.com/), a free database built to facilitate the evaluation of molecular methods for detection of SARS-CoV-2 and treatment of COVID-19.The database evaluates the available oligonucleotide sequences (PCR primers, RT-qPCR probes, etc.) considering the genetic diversity of the virus. Updated sequences alignments are used to constantly verify the theoretical efficiency of available testing methods. Detailed information on available detection protocols are also available to help laboratories implementing SARS-CoV-2 testing.

show abstract

Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species

Cited by 149 publications

References 15 publications

COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test

COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test

Toward understanding the 2019 Coronavirus and its impact on the heart

CoV2ID: Detection and Therapeutics Oligo Database for SARS-CoV-2

Contact Info

Product

Resources

About